For example, BRAF V600E mutation is strongly associated with aggressiveness and poor prognosis of PTC, while the expression levels of certain miRNAs may be associated with the risk of lymph node metastasis and recurrence (15). Here, BRAF is linked to metastatic malignant neoplasm in the lymph nodes.